Biomedicines · 2025 · 12 citations · 73 references
MedicineBioinformaticsOncologyMolecular OncologyPrecision MedicinePrecision OncologyCancer BiomarkersCirculating Tumor Dna AnalysisLiquid BiopsyMolecular Tumor ProfilingMulti-omics Data FusionOmics IntegrationBiomarker Discovery From Multi-omics DataCirculating Tumor Dna TestingExosomal BiomarkersIntegrated Multi-omics AnalysisLiquid Biopsy MarkersLiquid Biopsy ProfilingPrognostic Molecular StratificationTherapeutic Response Monitoring
Liquid biopsy and multi-omic biomarker integration are transforming precision oncology in breast cancer, providing real-time, minimally invasive insights into tumor biology. By analyzing circulating tumor DNA, circulating tumor cells, exosomal non-coding RNAs, and proteomic or metabolomic profiles, clinicians can monitor clonal evolution, therapeutic response, and recurrence risk in real time. Recent advances in sequencing technologies, methylation profiling, and artificial intelligence-driven data integration have markedly improved diagnostic sensitivity and predictive accuracy. Multi-omic frameworks combining genomic, transcriptomic, and proteomic data enable early detection of resistance, molecular stratification, and identification of actionable targets, while machine learning models enhance outcome prediction and therapy optimization. Despite these advances, key challenges persist. Pre-analytical variability, lack of standardized protocols, and disparities in access continue to limit reproducibility and clinical adoption. High costs, incomplete regulatory validation, and the absence of definitive evidence for mortality reduction underscore the need for larger, prospective trials. Integrating multi-omic assays into clinical workflows will require robust bioinformatics pipelines, clinician-friendly reporting systems, and interdisciplinary collaboration among molecular scientists, data engineers, and oncologists. In the near future, liquid biopsy is expected to complement, not replace, traditional tissue analysis, serving as a cornerstone of adaptive cancer management. As sequencing becomes faster and more affordable, multi-omic and AI-driven analyses will allow earlier detection, more precise treatment adjustments, and continuous monitoring across the disease course. Ultimately, these innovations herald a shift toward real-time, data-driven oncology that personalizes breast cancer care and improves patient outcomes.
73
Current and future burden of breast cancer: Global statistics for 2020 and 2040
Melina Arnold, Eileen Morgan, Harriet Rumgay et al. · The Breast · 2022 · 3.2K citations · Full text
Javier Pascual, Gerhardt Attard, François‐Clément Bidard et al. · Annals of Oncology · 2022 · 664 citations · Full text
Multi-omic machine learning predictor of breast cancer therapy response
Stephen‐John Sammut, Mireia Crispin‐Ortuzar, Suet‐Feung Chin et al. · Nature · 2021 · 642 citations · Full text
Medicine, Cancer Biology, Oncology +17
Ryan Woodhouse, Meijuan Li, Jason D. Hughes et al. · PLoS ONE · 2020 · 495 citations · Full text